Τίτλος:
A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: This observational case registry study was designed to describe the natural history of cancer patients with medication-related osteonecrosis of the jaw (ONJ) and evaluate the ONJ resolution rate. Methods: Adults with a diagnosis of cancer and with a new diagnosis of ONJ were enrolled and evaluated by a dental specialist at baseline and every 3 months for 2 years and then every 6 months for 3 years until death, consent withdrawal, or loss to follow-up. The primary endpoint was the rate and time course of ONJ resolution. Secondary endpoints included frequency of incident ONJ risk factors, ONJ treatment patterns, and treatment patterns of antiresorptive agents for subsequent ONJ. Results: Overall, 327 patients were enrolled; 207 (63%) were continuing on study at data cutoff. Up to 69% of evaluable patients with ONJ had resolution or improvement during the study. ONJ resolution (AAOMS ONJ staging criteria) was observed in 114 patients (35%); median (interquartile range) time from ONJ onset to resolution was 7.3 (4.5–11.4) months. Most patients (97%) had received antiresorptive medication before ONJ development, 9 patients (3%) had not; 68% had received zoledronic acid, 38% had received denosumab, and 10% had received pamidronate (56% had received bisphosphonates only, 18% had received denosumab only, and 21% had exposure to both). Conclusions: These results are consistent with those observed in clinical trials evaluating skeletal-related events in patients with advanced malignancy involving bone. Longer follow-up will provide further information on ONJ recurrence and resolution rates between medically and surgically managed patients. © 2017, The Author(s).
Συγγραφείς:
Schiodt, M.
Vadhan-Raj, S.
Chambers, M.S.
Nicolatou-Galitis, O.
Politis, C.
Coropciuc, R.
Fedele, S.
Jandial, D.
Zhang, J.
Ma, H.
Saunders, D.P.
Περιοδικό:
Supportive Care in Cancer
Λέξεις-κλειδιά:
aminoglycoside antibiotic agent; amoxicillin plus clavulanic acid; angiogenesis inhibitor; antifungal agent; bevacizumab; bisphosphonic acid derivative; cabozantinib; cephalosporin derivative; clindamycin; corticosteroid; cotrimoxazole; denosumab; immunosuppressive agent; macrolide; metronidazole; mouthwash; pamidronic acid; penicillin derivative; penicillin V potassium; protein kinase inhibitor; quinoline derived antiinfective agent; sorafenib; sultamicillin; sunitinib; tetracycline derivative; vancomycin; zoledronic acid; bisphosphonic acid derivative; bone density conservation agent; denosumab, adult; advanced cancer; aged; Article; bone tumor; breast cancer; cancer patient; cancer registry; dental caries; drug exposure; female; follow up; giant cell tumor; human; incidence; jaw osteonecrosis; major clinical study; male; multiple myeloma; periodontal disease; priority journal; prostate cancer; risk benefit analysis; risk factor; solid malignant neoplasm; tooth extraction; clinical trial; complication; disease exacerbation; jaw osteonecrosis; middle aged; multicenter study; neoplasm; pathology; register, Adult; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms; Registries; Risk Factors
DOI:
10.1007/s00520-017-4003-2
